EFPIA Mission Possible
This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
Search
Neovascular AMD (wet AMD)
Neovascular AMD (or wet AMD) is a severe form of advanced age-related macular degeneration that can lead to irreversible vision loss if untreated
What are lay summaries
Boehringer Ingelheim produces lay summaries of clinical trials, making complex information and data from clinical studies understandable for patients and carers.
Building Successful Partnerships in Animal Health
Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Stargardt Disease
Stargardt Disease is a hereditary condition which causes degeneration of cells in the retina at the back of the eye.
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
10 things you should know about rabies
10 things you should know about rabies
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Geographic Atrophy
Geographic atrophy (GA) is an advanced and severe form of dry age-related macular degeneration (AMD) that progresses slowly but can lead to permanent vision loss.
Diabetic macular edema and diabetic macular ischemia
Diabetic macular edema and diabetic macular ischemia are complications of diabetic retinopathy.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Croatia
CT-155: Prescription digital therapeutic
CT-155: Prescription digital therapeutic
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Zoonotic diseases things you should know
Zoonotic diseases can be transmitted between animals and humans. They are more common than you may think – and they are on the rise. Find out how this affects you.
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Diabetic Retinopathy
Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age.
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
Connect with your heart
If you know someone who has #type2diabetes, they are twice as likely to develop heart failure than those without.
Anna Race
Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
"Medical innovations and healthcare for everyone"
African Americans are often excluded from healthcare options and medical innovations. We want to learn how we can better serve them.
Supporting local communities by offsetting carbon emissions
Boehringer Ingelheim partially offsets its carbon emissions by partnering with ClimateSeed